Videos

Drs Obeidat and Okai discuss long-term data with oral DMTs that were recently presented at ACTRIMS 2022.

MS experts highlight the value of monitoring and use of risk mitigation strategies when taking care of patients with MS.

The director of the Stanford Stroke Center and Coyote Foundation Professor of Neurology and Neurological Sciences at Stanford Medical Center shared his perspective on the uptake of mobile stroke units across the United States. [WATCH TIME: 6 minutes]

Julio R. Vieira, MD, leads a discussion on the importance of follow-up visits for patients with migraine and considerations for switching therapies.

Andrew C. Charles, MD; Bradley Torphy, MD; and Jessica Ailani, MD, review current FDA approved CGRP monoclonal antibodies available for the preventive treatment of migraine.

Robert A. Hauser, MD, MBA, discusses the appearance of OFF episodes throughout progression of Parkinson disease.

Laxman Bahroo, DO, and Rajesh Pahwa, MD, comment on the identification and presentation of OFF episodes in patients with Parkinson disease.

The executive director of the Bensalem Rescue Squad spoke specifically to how the MSU has shifted the paradigm of care that EMS can provide to individuals in the community. [WATCH TIME: 4 minutes]

The assistant professor of neurology at The Ohio State University Wexner Medical Center provided insight on finding strategies to prevent neurodegeneration in multiple sclerosis. [WATCH TIME: 3 minutes]

The director of the Division of Movement Disorders at the USC Keck School of Medicine discussed the early reactions behind reflex tears as a potential biomarker for Parkinson disease. [WATCH TIME: 2 minutes]

The founder and chief medical officer of Omniscient Neurotechnology provided insight on the successes using connectomics, including the FDA approval of Quicktome, a digital brain mapping platform. [WATCH TIME: 4 minutes]

Neurology News Network for the week ending May 21, 2022. [WATCH TIME: 4 minutes]

Dr Barry A. Hendin reviews the use of high efficacy therapy in MS.

Regina Berkovich, MD, PhD, defines inflammation in multiple sclerosis and its role in MS pathogenesis.

The founder and chief medical officer of Omniscient Neurotechnology discussed the idea behind connectomics and how AI revolutionizes large-scale brain data. [WATCH TIME: 4 minutes]

The chief of emergency medical services at Jefferson Health shared his perspective on the first 2 years of the Jefferson MSU’s use and what takeaways he has gleaned from the experience. [WATCH TIME: 3 minutes]

The chief medical partner of neurology, ophthalmology, and internal medicine at Genentech shared his perspective on the steps the field has taken to improve clinical trials and therapies for neurodegenerative diseases such as Alzheimer disease. [WATCH TIME: 3 minutes]

Dr Okai provides an overview of oral DMTs available to patients with RRMS.

The co-CEOs and co-founders of Amylyx Pharmaceuticals discussed their immediate thoughts to the recent FDA AdComm meeting, which voted against evidence of efficacy for AMX0035 in ALS. [WATCH TIME: 3 minutes]

Two MS experts discuss shared decision-making and other considerations in choosing MS treatment.

Robert A. Hauser, MD, MBA, and Rajesh Pahwa, MD, define the difference between ON time and OFF episodes for patients with Parkinson disease.

Experts in headache medicine discuss the role of CGRP-based therapy for migraine prevention.

Rajesh Pahwa, MD, reviews the use of levodopa for the management of Parkinson disease symptoms.

Drs Bradley Torphy and Jessica Ailani share thoughts on using consensus statements to guide the treatment of migraine.

The chief executive officer of the Child Neurology Foundation provided insight on her new position at the National Health Institute’s National Advisory Neurological Disorders and Stroke Council. [WATCH TIME: 4 minutes]

David G. Standaert, MD, PhD; Wolfgang Muhlhofer, MD; and Latisha Sharma, MD, share their experience in applying simulation-based learning in Neurology and will discuss the current state and future potential of this approach. [WATCH TIME: 1 hour, 25 minutes]

In light of ALS Awareness Month, the associate professor of neurology at Columbia University discussed the ways in which advocacy has provided a platform for patients and improved conversations in care. [WATCH TIME: 6 minutes]

Neurology News Network for the week ending May 14, 2022. [WATCH TIME: 4 minutes]

Barry A. Hendin, MD, discusses innate and adaptive immunity and BTK inhibitors in the treatment of multiple sclerosis (MS).

Barry A. Hendin, MD, and Regina Berkovich, MD, PhD, provide an overview of the immune system, focusing on innate vs adaptive immunity, in the management of multiple sclerosis.